Savara (NASDAQ:SVRA) Trading Down 3.9%

Savara Inc (NASDAQ:SVRA)’s stock price was down 3.9% on Wednesday . The company traded as low as $4.96 and last traded at $4.96. Approximately 751,563 shares changed hands during mid-day trading, a decline of 9% from the average daily volume of 828,314 shares. The stock had previously closed at $5.16.

Wall Street Analyst Weigh In

Several brokerages have commented on SVRA. Piper Sandler boosted their target price on shares of Savara from $7.00 to $16.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th. JMP Securities began coverage on shares of Savara in a research report on Thursday, February 15th. They set an “outperform” rating and a $8.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $8.20.

Savara Stock Performance

The firm’s 50-day simple moving average is $4.96 and its 200 day simple moving average is $4.38. The company has a debt-to-equity ratio of 0.19, a quick ratio of 15.66 and a current ratio of 15.66.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Thursday, March 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02. Analysts forecast that Savara Inc will post -0.38 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in SVRA. Jennison Associates LLC raised its stake in shares of Savara by 128.0% during the 4th quarter. Jennison Associates LLC now owns 8,815,358 shares of the company’s stock worth $41,432,000 after buying an additional 4,948,596 shares during the last quarter. BlackRock Inc. raised its stake in Savara by 369.0% in the 2nd quarter. BlackRock Inc. now owns 4,898,576 shares of the company’s stock valued at $15,651,000 after purchasing an additional 3,854,198 shares during the last quarter. Wellington Management Group LLP acquired a new position in Savara in the 4th quarter valued at about $9,683,000. Vivo Capital LLC acquired a new position in Savara in the 3rd quarter valued at about $7,232,000. Finally, Adage Capital Partners GP L.L.C. raised its stake in Savara by 30.9% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 7,938,551 shares of the company’s stock valued at $30,008,000 after purchasing an additional 1,874,000 shares during the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.